Abstracts tagged "interstitial lung disease"

Abstract Number: 1171 • ACR Convergence 2022
Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
Phan Saligrama¹, Erin Wilfong², Elise Rizzi³, Leslie Crofford² and Peggy Kendall¹, ¹Washington University, Saint Louis, MO, ²Vanderbilt University Medical Center, Nashville, TN, ³Pennsylvania State University, Hershey, PA
Background/Purpose: The pathogenesis of systemic sclerosis is not well understood. The key differences between immune cell compartments in scleroderma with and without interstitial lung disease…
Abstract Number: 1533 • ACR Convergence 2022
Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
Alexandru Garaiman¹, Carina Mihai¹, Rucsandra Dobrota¹, cosimo bruni², Muriel Elhai¹, Suzana Jordan¹, Lea Stamm³, Anna-Maria Hoffmann-vold⁴, Oliver Distler¹ and Mike Becker¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²University of Florence, Florence, Italy, ³Department of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: Some gastrointestinal (GI) and nutritional factors are associated with the presence of interstitial lung disease related to systemic sclerosis (SSc-ILD). However, there are many…
Abstract Number: 2165 • ACR Convergence 2022
Patients with Systemic Sclerosis Have Impaired Forced Vital Capacity, Even in the Absence of Interstitial Lung Disease
Håvard Fretheim, Imon Barua, Øyvind Midtvedt, Torhild Garen, Phoung Phoung Diep, Michael Durheim, Cathrine Brunborg and Anna-Maria Hoffmann-vold, Oslo University Hospital, Oslo, Norway
Background/Purpose: Spirometry, in particular forced vital capacity (FVC), is a widely implemented tool in the initial diagnostic workup and monitoring of systemic sclerosis-related interstitial lung…
Abstract Number: 0140 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Müller⁶, Carl Coeck⁷, Klaus Rohr⁸ and Wim Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital…
Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 1178 • ACR Convergence 2022
Key Features of Human Fibrosing Interstitial Lung Disease Are Captured in a Preclinical Mouse Model upon Repetitive, but Not Single Intratracheal Bleomycin Dosing
David Lauer¹, Janine Schniering², Matthias Brunner¹, Chantal Meier³, Kerstin Klein¹, Oliver Distler⁴ and Britta Maurer¹, ¹Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland, ²Helmholtz Zentrum München, Institute of Lung Health and Immunity (LHI), Comprehensive Pneumonology Center, Munich, Germany, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Repetitive alveolar epithelial injury together with dysregulated tissue repair is crucial for the transition of acute self-limiting to chronic-persisting inflammation and fibrosis in fibrosing…
Abstract Number: 1536 • ACR Convergence 2022
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
Anna-Maria Hoffmann-Vold¹, Cathrine Brunborg¹, Paolo Airò², Lidia P. Ananyeva³, László Czirják⁴, Serena Guiducci⁵, Eric Hachulla⁶, MENGTAO LI⁷, Carina Mihai⁸, Gabriela Riemekasten⁹, Petros P. Sfikakis¹⁰, Gabriele Valentini¹¹, Otylia Kowal-Bielecka¹², Yannick Allanore¹³ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ³V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴Medical school of Pécs, Pecs, Hungary, ⁵University of Firenze, Firenze, Italy, ⁶University of Lille, Lille, France, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁹University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁰Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ¹¹Università della Campania “Luigi Vanvitelli”, Napoli, Italy, ¹²Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…
Abstract Number: 2172 • ACR Convergence 2022
Pulmonary Function in Patients Diagnosed of Early Systemic Sclerosis: 10 Years-Experience
Samuel Leal Rodriguez¹, Francisco Miguel Ortiz Sanjuan², José Ivorra Cortés³, Laura Mas Sanchez³, Pablo Muñoz Martinez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales³, Inés Cánovas Olmos³, Luis Gonzalez Puig⁷, Elena Grau García³, Isabel Martínez-Cordellat³, Carmen Nájera Herranz³, Rosa Negueroles Albuixech³, JOSE ELOY OLLER RODRIGUEZ⁸, Elvira Vicens Bernabeu², Alba Torrat Novés⁵, Daniel Ramos Castro³ and José andrés Román ivorra¹, ¹Hospital Universitari i Politécnic La Fe, València, Spain, ²Hospital Universitario de La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital La Fe, Torrente, Valencia, Spain, ⁸Hospital Universitario de La Fe, València, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), often progressive and has a poor prognosis. A restrictive ventilatory defect could…
Abstract Number: 0289 • ACR Convergence 2021
Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
Pierre Antoine Juge¹, Benjamin Granger², Marie-Pierre Debray³, Esther Ebstein⁴, Fabienne Louis-sidney⁵, Joanna Kedra⁶, Raphaël Borie⁷, Arnaud Constantin⁸, Bernard Combe⁹, Rene-Marc FLIPO¹⁰, Xavier Mariette¹¹, Olivier Vittecoq¹², Alain Saraux¹³, Guillermo CARVAJAL-ALEGRIA¹⁴, Jean Sibilia¹⁵, Francis Berenbaum¹⁶, Caroline Kannengiesser¹⁷, Catherine Boileau¹⁷, Bruno Crestani¹⁸, Bruno Fautrel¹⁹ and Philippe Dieudé²⁰, ¹Hopital Bichat-Claude Bernard, Service de Rhumatologie, Paris, France, ²Département de Santé Publique, Hopital de la Pitié Salpétrière, Paris, France, ³Hopital Bichat, Service de Radiologie, Paris, France, ⁴Hopital Bichat, Service de Rhumatologie, Paris, ⁵University Hospital Martinique, Fort de France, Martinique, ⁶Sorbonne Universit, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France, ⁷Hopital Bichat, Service de Pneumologie, Paris, ⁸Toulouse University Hospital, Toulouse Cedex 9, France, ⁹CHU Montpellier Montpellier University, Montpellier, France, ¹⁰Lille University Hospital, Lille, France, ¹¹Université Paris- Saclay, Rheumatology, Paris, France, ¹²CHU de Rouen, Service de Rhumatologie, Rouen, France, ¹³CHU de Brest, Brest Cedex, France, ¹⁴CHU de Brest, Service de Rhumatologie, Brest, ¹⁵CHU de Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁶Sorbonne Universit - hopital Saint-Antoine, Paris, France, ¹⁷CHU de Bichat, Service de Génétique, Paris, France, ¹⁸Hopital Bichat, Paris University, Paris, France, ¹⁹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²⁰CHU de Bichat, Service de Rhumatologie, Paris, France
Background/Purpose: Interstitial lung disease (ILD) can be detected in 20% to 60% of patients with rheumatoid arthritis (RA) on high-resolution computed-tomography (HRCT) chest scan and…
Abstract Number: 0529 • ACR Convergence 2021
COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
Sarah Beshay¹, Isabella Osuna², Jessica Smith¹, Justin Branch³, Laura Muruato³, Marietta DeGuzman³, Pamela McShane¹, Yuelan Ren¹, Rajeev Singh¹, Manuel Silva Carmona³, Sandeep Sahay¹ and Tiphanie Vogel³, ¹Houston Methodist, Houston, ²Rice University, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: COPA syndrome is a rare monogenic cause of immune-mediated lung disease, and it can mimic rheumatic diseases including rheumatoid arthritis (RA) with ILD, lupus…
Abstract Number: 1101 • ACR Convergence 2021
Atypical Pulmonary Radiographic Findings May Help Identify Patients with Usual Interstitial Pneumonia and Autoimmune Features
Fredeswinda Romero Bueno¹, Carmelo Palacios¹, Maria Jesus Rodriguez Nieto¹, Maria Tello Lasheras¹, Angel Rodriguez Leon², Maria Carmen Vegas Sanchez¹, Gabriel Herrero-Beaumont³ and Olga Sanchez Pernaute¹, ¹University Hospital "Fundación Jimenez Diaz", Madrid, Spain, ²Autonoma University of Madrid, Madrid, Spain, ³University Hospital "Fundacion Jimenez Diaz", Madrid, Spain
Background/Purpose: Once specific etiologic factors have been ruled out, the majority of patients with chronic interstitial pneumonia (IP) can be classified as idiopathic pulmonary fibrosis…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0561 • ACR Convergence 2021
Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports
Brent Luedders¹, Brendan Cope², Matt Devries², W. Scott Campbell², James Campbell², Ted Mikuls³, Jeffrey Curtis⁴, Daniel Hershberger³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, NE, United Kingdom, ²University of Nebraska Medical Center, Omaha, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interstitial lung disease (ILD) is an extraarticular manifestation of RA that leads to increased morbidity and mortality. Algorithms incorporating multiple diagnostic and procedure codes…
Abstract Number: 1372 • ACR Convergence 2021
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
Soumyasri Kambhatla¹, Augustine Manadan² and Amy Trang², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].